Functional Neuromodulation Ltd. is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with Alzheimer’s and other memory and cognitive disorders. The company is investigating the use of DBS of the fornix (DBS-f) to drive neural activity and modulate the brain’s memory circuit. The company has raised a total of $13.4 in funding commitments from Genesys Capital, Foundation Medical Partners and Medtronic, Inc. Building on early clinical data, the company has initiated the ADvance Study, a multi-center feasibility study of DBS-f in patients with mild Alzheimer’s. Enrollment of ADvance was completed in April 2014 and top-line outcomes data are expected in the second quarter of 2015. The ADvance Study is also supported through a translational grant of up to $2.75M from the National Institute on Aging, part of the National Institutes of Health.
CAUTION — Investigational device. Limited by Federal law to investigational use.
Functional Neuromodulation, Ltd. | 200 Front Street West | Suite 3004 | P.O. Box 31 | Toronto, Ontario M5V 3K2 | (866) 296-4040 | email@example.com
© 2014 Functional Neuromodulation Ltd. All rights reserved.